Skip to main content
. 2017 Oct 10;8(61):103744–103757. doi: 10.18632/oncotarget.21781

Figure 6. Presence of Shh+ cells in fresh human NSCLC tissue samples.

Figure 6

(A) Flow cytometric analysis of Shh in a fresh human NSCLC sample [†CD45+ cells; ‡CD45-Shh- cells; ₮CD45-Shh+ cells (2.99% of CD45- cells)]. (B) Flow cytometric analysis of Shh in a fresh human normal lung sample [†CD45+ cells; ‡CD45-Shh- cells; ₮CD45-Shh+ cells (0%)]. (C) Percentage of Shh+ cells (%) in fresh human NSCLC samples and corresponding normal lung tissues (n=48). (D) Percentage of Shh+ cells (%) in primary lung adenocarcinoma with a tumor response after chemotherapy and the corresponding adrenal metastasis with tumor progression after chemotherapy in the same patient. (E) Time-to-progression (TTP) according to high (>0.10%) or low (<0.10%) percentage of Shh+ cells (p<0.01 for log-rank test) in stage I NSCLC tissue samples (n=32). (F) Percentage of Shh+ cells (%) in stage I NSCLC with tumor relapse <12 months after surgery (n=6) and in stage I NSCLC without relapse within 12 months after surgery (n=16) (**p<0.01).